We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — — KB-0742 continues to show dose linear pharmacokinetics up to 80mg...
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at...
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today...
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.02555 | 3.35059996066 | 0.76255 | 0.83 | 0.74 | 354706 | 0.77629062 | CS |
| 4 | -0.2319 | -22.7352941176 | 1.02 | 1.09 | 0.69 | 421164 | 0.91501371 | CS |
| 12 | -0.5619 | -41.6222222222 | 1.35 | 1.4 | 0.69 | 384943 | 1.00881413 | CS |
| 26 | -0.3919 | -33.2118644068 | 1.18 | 1.5053 | 0.69 | 312564 | 1.07699961 | CS |
| 52 | -0.8519 | -51.9451219512 | 1.64 | 2.29 | 0.69 | 294485 | 1.2229691 | CS |
| 156 | -26.1719 | -97.0767804154 | 26.96 | 28.42 | 0.69 | 301186 | 5.91524728 | CS |
| 260 | -27.5019 | -97.2142099682 | 28.29 | 39.605 | 0.69 | 286875 | 9.15143494 | CS |
glenn1919
2 months ago
Monksdream
2 months ago
glenn1919
3 months ago
Monksdream
3 months ago
Monksdream
7 months ago
Monksdream
8 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
